Neurocognitive effects of kava (Piper methysticum): A systematic review

Human Psychopharmacology

Volumn 26, Issue 2, 2011, Pages 102-111

  Laporte, E ^a   Sarris, J ^a,b   Stough, C ^a,c   Scholey, A ^a,c  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NICM Collaborative Centre for Neurocognition   (Australia)

Author keywords

adverse effects; anxiety; cognition; driving; kava; kavalactones; Piper methysticum

Indexed keywords

4 AMINOBUTYRIC ACID; ALCOHOL; CLOBAZAM; DIHYDROKAWAIN; KAVA EXTRACT; KAWAIN; NORADRENALIN; OXAZEPAM; PLACEBO;

ATTENTION; BODY EQUILIBRIUM; CINAHL; COCHRANE LIBRARY; COGNITION; DRUG OVERDOSE; HUMAN; MEDLINE; MEMORY; PIPER METHYSTICUM; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCINFO; REVIEW; SYSTEMATIC REVIEW; WORKING MEMORY;

ANIMALS; ATTENTION; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; KAVA; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 79956264661     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1180     Document Type: Review

References (51)

1. Amorim MFD, Diniz MFFM, et al,. 2007. " The controvertible role of kava (Piper methysticum G. Foster) an anxiolytic herb, on toxic hepatitis." Rev bras farmacogn 17 (3): 448-454.
2. Bilia AR, Gallon S, et al,. 2002. " Kava-kava and anxiety: growing knowledge about the efficacy and safety." Life Sci 70 (22): 2581-2597. (Pubitemid 34326436)
3. Boonen G, Häberlein H., 1998. " Influence of genuine kavapyrone enantiomers on the GABAA binding site." Planta Med 64: 504-506. (Pubitemid 28383880)
4. Buffet-Jerrott SE, Stewart SH, et al,. 1998. " A further exmination of the time-dependent effects of oxazepam and lorazepam on implicit and explicit memory." Psychopharmacology (3-4) (138): 344-353. (Pubitemid 28365500)
5. Cairney S, Maruff P, et al,. 2002. " The neurobehavioural effects of kava." Aust N Z J Psychiatry 36 (5): 657-662. (Pubitemid 35174406)
6. Cairney S, Clough AR, et al,. 2003a. " Saccade and cognitive function in chronic kava users." Neuropsychopharmacology 28 (2): 389-396.
7. Cairney S, Maruff P, et al,. 2003b. " Saccade and cognitive impairment associated with kava intoxication." Hum Psychopharmacol 18 (7): 525-533. (Pubitemid 37279234)
8. Clouatre DL., 2004. " Kava kava: examining new reports of toxicity." Toxicol Lett 150 (1): 85-96. (Pubitemid 38447238)
9. Cohen J., 1988. Statistical Power Analyses for the Behavioral Sciences. Erlbaum: Hillsdale.
10. Coulter D., 2007. " Assessment of the Risk of Hepatotoxicity with Kava Products." WHO Appointed Committee: Geneva.
11. Denham A, McIntyre M, et al,. 2002. " Kava-the unfolding story: report on a work-in-progress." J Altern Complement Med 8 (3): 237-263. (Pubitemid 34753400)
12. Foo H, Lemon J., 1997. " Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance." Drug Alcohol Rev 16 (2): 147-155. (Pubitemid 127531298)
13. Gleitz J, Beile A, et al,. 1997. " Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets." Planta Med 63 (1): 27-30. (Pubitemid 27112433)
14. Heinze HJ, Münte TF, et al,. 1994. " Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials." Pharmacopsychiatry 27 (6): 224-230. (Pubitemid 24337137)
15. Herberg KW., 1993. " Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters." Blutalkohol 30 (2): 96-105.
16. Jadad A, Moore A, et al,. 1996. " Assessing the quality of reports of randomised clinical trials: Is blinding necessary? " Control Clin Trials 17: 1-12. (Pubitemid 26120810)
17. Jamieson DD, Duffield PH., 1990. " Positive interaction of ethanol and kava resin in mice." Clin Exp Pharmacol Physiol 17 (7): 509-514. (Pubitemid 20242553)
18. Kobayashi K, Yasoshima Y., 2001. " The central noradrenaline system and memory consolidation." Neuroscientist 7 (5): 371-376. (Pubitemid 32923752)
19. Kretschemer W., 1974. " Mental effects of kavain." Münchener Medizinische Wochenschrift 116 (14): 741-742.
20. Mathews JD, Riley MD, et al,. 1988. " Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community." Med J Aust 148 (11): 548-555.
21. Mathews JM, Etheridge AS, et al,. 2002. " Inhibition of human cytochrome P450 activities by kava extract and kavalactones." Drug Metab Dispos 30 (11): 1153-1157. (Pubitemid 35265819)
22. Münte TF, Heinze HJ, et al,. 1993. " Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task." Neuropsychobiology 27 (1): 46-53. (Pubitemid 23165779)
23. Nerurkar PV, Dragull K, et al,. 2004. " In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones." Toxicol Sci 79 (1): 106-111. (Pubitemid 38660254)
24. Norton SA, Ruze P., 1994. " Kava dermopathy." J Am Acad Dermatol 31 (1): 89-97. (Pubitemid 24198170)
25. Pittler MH, Ernst E., 2000. " Efficacy of kava extract for treating anxiety: systematic review and meta-analysis." J Clin Psychopharmacol 20 (1): 84-89. (Pubitemid 30056358)
26. Pittler MH, Ernst E., 2003. " Kava extract for treating anxiety." Cochrane Database Syst Rev (1): CD003383.
27. Poolsup N, Li Wan Po A, et al,. 2000. " Pharmacogenetics and psychopharmacotherapy." J Clin Pharm Ther 25 (3): 197-220.
28. Prescott J, Jamieson D, et al,. 1993. " Acute effects of kava on measures of cognitive performance, physiological function and mood." Drug Alcohol Rev 12 (1): 49-57.
29. Raduege KM, Kleshinski JF, et al,. 2004. " Anesthetic considerations of the herbal, kava." J Clin Anesth 16 (4): 305-311. (Pubitemid 38917182)
30. Rotblatt MD., 1999. " Cranberry, feverfew, horse chestnut, and kava." West J Med 171 (3): 195-198.
31. Russell PN, Bakker D, et al,. 1987. " The effects of kava on altering and speed of access of information from long-term memory." Bull Psychon Soc 25 (4): 236-237.
32. Saletu B, Grunberger J, et al,. 1989. " EEG-Brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative." Hum Psychopharmacol 4: 169-190. (Pubitemid 19211779)
33. Sarris J, Byrne G., 2011. " A systematic review of insomnia and complementary medicine." Sleep Med Rev 15 (2): 99-106.
34. Sarris J, Kavanagh DJ., 2009. " Kava and St. John's Wort: current evidence for use in mood and anxiety disorders." J Altern Complement Med 15 (8): 827-836.
35. Sarris J, Adams J, et al,. 2009. " Time for a reassessment of Kava in anxiety? " Complement Ther Med 17: 121-122.
36. Sarris J, Kavanagh D, et al,. 2009. " The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum." Psychopharmacology (Berl) 205 (3): 399-407.
37. Schirrmacher K, Büsselberg D, et al,. 1999. " Effects of (+/-)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats." Eur Neuropsychopharmacol 9: 171-176. (Pubitemid 29073699)
38. Scholing WE, Clausen HD., 1977. " On the effect of d,l-kavain: experience with neuronika." Medizinische Klinik 72: 1301-1306.
39. Singh YN., 1992. " Kava: an overview." J Ethnopharmacol 37 (1): 13-45.
40. Singh YN, Singh NN., 2002. " Therapeutic potential of kava in the treatment of anxiety disorders." CNS Drugs 16 (11): 731-743. (Pubitemid 35252722)
41. Stevinson C, Huntley A, et al,. 2002. " A systematic review of the safety of kava extract in the treatment of anxiety." Drug Saf 25 (4): 251-261. (Pubitemid 34569359)
42. Teschke R., 2010. " Kava hepatotoxicity-a clinical review." Ann Hepatol 9 (3): 251-265.
43. Teschke R, Schwarzenboeck A, et al,. 2008. " Kava hepatotoxicity: a European view." N Z Med J 121 (1283): 90-98.
44. Teschke R, Sarris J, et al,. 2010. " Kava hepatotoxicity solution: a six-point plan for new kava standardization." Phytomedicine 1-8.
45. Thompson R, Ruch W, et al,. 2004. " Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava)." Hum Psychopharmacol 19 (4): 243-250. (Pubitemid 38868340)
46. Uebelhack R, Franke L, et al,. 1998. " Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)." Pharmacopsychiatry 31 (5): 187-192. (Pubitemid 28505910)
47. Uhlenhuth EH, DeWit H, et al,. 1988. " Risks and benefits of long-term benzodiazepine use." J Clin Psychopharmacol 8 (3): 161-167.
48. van Leeuwen TH, Verbaten MN, et al,. 1995. " Effects of oxazepam on event-related brain potentials, EEG frequency bands, and vigilance performance." Psychopharmacology (122): 244-262.
49. Wanwimolruk S, Bhawan S, et al,. 1998. " Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations." Eur J Clin Pharmacol 54 (5): 431-435. (Pubitemid 28396318)
50. Xian-guo H, Long-ze L, et al,. 1997. " Electrospray high performance liquid chromatography mass spectrometry in phytochemical analysis of Kava (Piper methysticum) extract." Planta Med 63: 70-74.
51. Zhou P, Gross S, et al,. 2010. " Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF- B and MAPK signaling pathways." FASEB J Res Commun 24: 1-24.